25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
-
Patent number: 8183210Abstract: Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders.Type: GrantFiled: April 13, 2009Date of Patent: May 22, 2012Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jan Johansson, Tore Curstedt, Bengt Robertson, Joakim Robertson, legal representative, Soeren Robertson, legal representative, Magnus Robertson, legal representative, Charlotte Robertson, legal representative, Gertie Robertson Grossmann, legal representative
-
Publication number: 20120121590Abstract: The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.Type: ApplicationFiled: April 16, 2010Publication date: May 17, 2012Inventors: Klaus Ley, Christian Gleissner
-
Publication number: 20120121602Abstract: Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and diagnostic methods. Antibodies which specifically recognize the polypeptides are also provided, as well as their uses. Characterization of each protein showed that PRT5 and PRT8 are involved in glucose metabolism, PRT6 is involved in androgen regulation, while PRT7 correlates with cancer.Type: ApplicationFiled: August 2, 2010Publication date: May 17, 2012Applicant: TWO TO BIOTECH LTD.Inventors: Tamara Sandler, Orly Devary
-
Publication number: 20120121601Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: January 13, 2012Publication date: May 17, 2012Applicant: Schering CorporationInventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Publication number: 20120114628Abstract: The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a polypeptide, especially for preventing and/or treating the signs of skin dryness. The invention also relates to the use of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof or of a nucleic acid sequence coding for such a polypeptide, as a marker for evaluating the state of dryness of an epithelium.Type: ApplicationFiled: November 19, 2009Publication date: May 10, 2012Applicant: L'OREALInventors: Dominique Bernard, Lucie Simonetti, Isabelle Castiel
-
Publication number: 20120115789Abstract: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS).Type: ApplicationFiled: May 26, 2010Publication date: May 10, 2012Inventors: Peter Nawroth, Angelika Bierhaus, Thomas Fleming
-
Publication number: 20120101042Abstract: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.Type: ApplicationFiled: March 18, 2010Publication date: April 26, 2012Applicants: Cincinnati Children's Hospital Medical Center, The Brigham and Women's Hospital, Inc.Inventors: Jeremy Duffield, Richard A. Lang
-
Patent number: 8163700Abstract: The present invention relates generally to products, compositions and methods useful for promoting neural repair and regeneration. The products and compositions of this invention include myelin-associated glycoprotein (MAG) derivatives that are inhibitors of endogenous MAG (e.g., mutant MAG proteins) and Nogo Receptor (NgR) binding inhibitors that are peptides derived from MAG, Nogo and OMgp that can bind to NgR and block NgR signaling. Peptides that can bind and activate NgR signaling are also provided. Inhibitory MAG derivatives and NgR binding inhibitors are useful for blocking the inhibition of neural regeneration mediated by proteins such as MAG, Nogo and/or OMgp in the nervous system. These inhibitors are also useful for treating neural degeneration associated with injuries, disorders or diseases.Type: GrantFiled: November 12, 2010Date of Patent: April 24, 2012Assignee: Research Foundation of City University of New YorkInventors: Marie T. Filbin, Marco Domeniconi, Zixuan Cao
-
Patent number: 8163874Abstract: Disclosed is a method of making peptide structures that are stable in aqueous and non-aqueous media where a first linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini is joined by at least one turn region to a second linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini. The peptide chains can be joined at the C terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain, a C terminus of one of the linear peptide chains with a C terminus of the other linear peptide chain, or an N terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain.Type: GrantFiled: August 6, 2008Date of Patent: April 24, 2012Assignee: The United States of America, as represented by the Secretary of the NavyInventors: John L Kulp, Thomas D Clark
-
Patent number: 8163696Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 (as mentioned in the introduction) and one or more of positions 3, 5, 7, 10 and 11, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy. Also disclosed are methods and kits for selecting a patient from populations suited for treatment with GLP-2 analogues.Type: GrantFiled: December 21, 2009Date of Patent: April 24, 2012Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Yvette Miata Petersen
-
Patent number: 8158588Abstract: The present invention provides polypeptides that contain one or more PDZ loop-variants and are useful in the detection of pathogens and disease-associated molecules. The polypeptides of the invention are also useful in the diagnosis, treatment, and prevention of diseases. Also provided are methods of preparing polypeptides of the invention.Type: GrantFiled: December 4, 2006Date of Patent: April 17, 2012Inventor: Simon Delagrave
-
Patent number: 8158582Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration.Type: GrantFiled: June 1, 2006Date of Patent: April 17, 2012Assignee: Tercica, Inc.Inventors: Ross G. Clark, Gillian Clark, legal representative
-
Publication number: 20120087865Abstract: A system, including methods and compositions, for treatment of ischemia.Type: ApplicationFiled: October 28, 2011Publication date: April 12, 2012Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: Roger P. SIMON, Zhi-Gang Xiong
-
Publication number: 20120088718Abstract: The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections.Type: ApplicationFiled: March 17, 2010Publication date: April 12, 2012Applicant: INSTITUT PASTEURInventors: Thomas Krey, Felix A. Rey, Carlos Massayuki Kikuti, Laurence Damier-Piolle
-
Patent number: 8153599Abstract: The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation.Type: GrantFiled: December 27, 2007Date of Patent: April 10, 2012Assignee: Mondobiotech AGInventor: Lutz-Henning Block
-
Patent number: 8153598Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands.Type: GrantFiled: October 18, 2006Date of Patent: April 10, 2012Assignee: Intrexon CorporationInventor: Thomas D. Reed
-
Patent number: 8153585Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.Type: GrantFiled: July 14, 2008Date of Patent: April 10, 2012Assignee: Children's Medical Center CorporationInventors: Michael Klagsbrun, Shay Soker
-
Publication number: 20120082619Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.Type: ApplicationFiled: July 7, 2011Publication date: April 5, 2012Inventors: Jocelyn Dupuis, Alain Fournier
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120082672Abstract: It is disclosed here that synaptotagmin I (syt I) and synaptotagmin II (syt II) are the cellular receptors for botulinum neurotoxin B (BoNT/B) that mediate the cellular entry and toxicity of BoNT/B. The BoNT/B binding domains of syt I and II are also disclosed. While syt I needs gangliosides for BoNT/B binding, syt II can bind to BoNT/B in the absence of gangliosides. Various nucleic acids and polypeptides that relate to the BoNT/B binding domain of syt I or II are disclosed. Further disclosed are methods of reducing BoNT/B toxicity, methods of identifying agents that can block the binding between BoNT/B and syt I or II, methods of identifying agents that can bind to the BoNT/B binding domain of syt I or II, methods of detecting BoNT/B or Clostridium botulinum and kits for use thereof.Type: ApplicationFiled: October 26, 2011Publication date: April 5, 2012Inventors: Edwin Raymond Chapman, Min Dong
-
Patent number: 8148333Abstract: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.Type: GrantFiled: October 3, 2007Date of Patent: April 3, 2012Assignees: Radius Health, Inc., Ipsen Pharma S.A.S.Inventors: Michael J. Dey, Nathalie Mondoly, Benedicte Rigaud, Bart Henderson, C. Richard Lyttle
-
Patent number: 8148492Abstract: The present invention is directed to a reconstituted surfactant comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. The invention is also directed to the pharmaceutical compositions thereof and to a use thereof in the treatment or prophylaxis of RDS and other respiratory disorders.Type: GrantFiled: August 11, 2008Date of Patent: April 3, 2012Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jan Johansson, Tore Curstedt, Bengt Robertson, Maurlzio Delcanale
-
Patent number: 8147819Abstract: Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angstroms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.Type: GrantFiled: January 11, 2011Date of Patent: April 3, 2012Assignee: Vax ConsultingInventor: Jean-Francois Zagury
-
Patent number: 8143222Abstract: Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kd of less than about 10?7 M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide, a polypeptide, a peptidomimetic, a protein or a protein domain, and wherein the targeting moiety and the pharmaceutically active moiety are covalently attached. In some aspects, the targeting moiety binds a sigma-2 receptor with high affinity and high specificity, and the pharmaceutically active moiety is a pro-apoptotic peptide moiety. Methods of cancer treatment are disclosed comprising administering a disclosed pharmaceutical compound to a subject in need of thereof. The treatments selectively induce apoptosis in cancer cells. These methods can further comprise co-administration of radiation therapy and/or an additional chemotherapeutic agent.Type: GrantFiled: October 22, 2008Date of Patent: March 27, 2012Assignee: Washington UniversityInventors: Jonathan E. McDunn, William G. Hawkins, Robert H. Mach, Richard A. Hotchkiss
-
Patent number: 8142764Abstract: The present invention provides streptococcal SspB Adherence Region (BAR) peptides consisting of Formula I: R18-R1- R2-Val-R3-R4-Leu-Leu-R5-R6-R7-Ile-R8-R9-Lys-R10-R19 , wherein R2, is 1-3 Lys residues; R3 is any amino acid residue except a Pro residue; R4 is any amino acid residue except a Pro residue; R5 is 1-3 Lys residues; R6 is 1-10 amino acid residues; R7 is any amino acid residue except Asp, Glu, Gly or Pro; R8 is any amino acid residue except Ala, Asp, Gly, His, Ile, Pro, Trp or Tyr; R9 is a Val, Ile, Phe, or Trp residue; R10 is 0-1 Cys residue; R18 is 0 amino acids or R12-R11-Pro-, wherein R11 is 0-3 amino acids, wherein the amino acid residues are not Gly or Pro; and R12 is 0-1 Cys residues; and R19 is R13-R14-R15-R16-R17, wherein R13 is 0-1 is Gly residue; R14 is 0-1 Ala residue; R15 is 0-1 Phe residue; R16 is 0-1 Gln residue; R17 is 0-1 Cys residue; and wherein R1 is an ornithine residue; or wherein both R1 and R10 are both Cys and R1 and R10 are covalently linked to form a circular peptide; or wheType: GrantFiled: February 25, 2009Date of Patent: March 27, 2012Assignee: University of Louisville Research FoundationInventors: Donald R. Demuth, Carlo Amorin Daep
-
Patent number: 8143374Abstract: The present invention is related to novel parathyroid hormone polypeptide derivatives, and to pharmaceutical composition containing the polypeptides, as well as synthetic and recombinant methods for producing the polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing the polypeptides of the present invention. The present invention further provides diagnostic and therapeutic methods using the polypeptide derivatives.Type: GrantFiled: August 3, 2007Date of Patent: March 27, 2012Assignee: The General Hospital CorporationInventors: Henry M. Kronenberg, John T. Potts, Jr., Thomas J. Gardella
-
Publication number: 20120071394Abstract: The present invention provides a polypeptide having a biological activity of the Chemotaxis Inhibitory Protein of Staphylococcus aureus (‘CHIPS’), the polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof having a biological activity of CHIPS, wherein the fragment or variant retains amino acid substitutions K40E, D42V, N77H, K100R, K105R, N111 K and/or G112A relative to the wildtype CHIPS protein of SEQ ID NO:1. In one embodiment, polypeptide consists of the amino acid sequence of SEQ ID NO: 2. Related aspects of the invention provide pharmaceutical compositions comprising a polypeptide of the invention, together with methods or making and using the same.Type: ApplicationFiled: November 30, 2009Publication date: March 22, 2012Inventors: Christina Furebring, Anna Rosén, Karin Haraldsson, Erika Gustafsson, Björn Ulrik Walse
-
Publication number: 20120066775Abstract: The invention provides novel nucleic acids and polypeptides, referred to herein as stresscopin 1 and stresscopin 2, which preferentially activate the CRH-R2 receptor over the R1 receptor. Stresscopins, analogs and mimetics, and related CRH-R2 agonists suppress food intake and heat-induced edema; but do not induce substantial release of ACTH. Stresscopin also finds use in the recovery phase of stress responses, as an anti-inflammatory agent, as a hypotensive agent, as a cardioprotective agent, and in the treatment of psychiatric and anxiolytic disorders. Stresscopin nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways.Type: ApplicationFiled: October 1, 2010Publication date: March 15, 2012Inventors: Sheau Yu Hsu, Aaron J.W. Hsueh
-
Patent number: 8133859Abstract: The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.Type: GrantFiled: September 27, 2007Date of Patent: March 13, 2012Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shioko Kimura, Reiko Kurotani
-
Publication number: 20120058956Abstract: Provided are peptides having a sequence that is a subsequence of a ficolin protein and methods of use thereof. The peptide may be a subsequence of human ficolin in which case it is essentially non-toxic. Further provided is a pharmaceutical composition including such peptides. The pharmaceutical composition can include an active ingredient for delivery through a body surface such as skin.Type: ApplicationFiled: March 3, 2010Publication date: March 8, 2012Applicant: METAMOREFIX LTD.Inventors: Mazal Dahan, Ascher Shmulewitz
-
Publication number: 20120058119Abstract: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, David Hilbert
-
Publication number: 20120058933Abstract: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.Type: ApplicationFiled: May 8, 2008Publication date: March 8, 2012Applicant: University of Louisville Research FoundationInventor: Sven-Ulrik Gorr
-
Patent number: 8129345Abstract: The disclosure provides methods of identifying and making compounds and pharmaceutical compositions containing the compounds that inhibit the interaction between MUC1 and an IKK. The disclosure also provides in vivo and in vitro methods of inhibiting such an interaction. Also embraced by the disclosure are in vitro and in vivo methods of inhibiting the IKK/NF-?B pathway in cells expressing MUC1. The compounds, compositions, and methods of the disclosure are generally useful in the treatment of various cancers, inflammatory (e.g., autoimmune disorders), and transplant rejection.Type: GrantFiled: July 20, 2007Date of Patent: March 6, 2012Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Donald W. Kufe
-
Patent number: 8129332Abstract: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.Type: GrantFiled: April 11, 2008Date of Patent: March 6, 2012Assignee: Arizona Board of RegentsInventors: Colleen Brophy, Alyssa Panitch, Padmini Komalavilas, Brandon Seal, Lokesh Joshi
-
Patent number: 8129330Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: GrantFiled: September 25, 2003Date of Patent: March 6, 2012Assignee: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L Martinez, Merry R Sherman, Mark G. P. Saifer, L. David Williams
-
Patent number: 8129331Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.Type: GrantFiled: December 7, 2007Date of Patent: March 6, 2012Assignee: Amgen Inc.Inventors: Jonathan Daniel Oliner, Hosung Min
-
Patent number: 8124579Abstract: The present invention provides novel HSP20-based polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses.Type: GrantFiled: October 15, 2004Date of Patent: February 28, 2012Assignee: Arizona Board of RegentsInventors: Colleen Brophy, Elizabeth Furnish, Padmini Komalavilas, Catherin Dreiza, Alyssa Panitch
-
Publication number: 20120046224Abstract: Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating insulin resistance, and for reducing serum glucose levels.Type: ApplicationFiled: March 10, 2010Publication date: February 23, 2012Applicant: NORDIC BIOSCIENCE A/SInventors: Morten A. Karsdal, Claus Christiansen
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Publication number: 20120040886Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Zheng Xin Dong
-
Publication number: 20120040918Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.Type: ApplicationFiled: March 13, 2009Publication date: February 16, 2012Applicant: CTI BIOInventors: Jong-Ook Lee, Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim
-
Publication number: 20120040885Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20120040915Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: ApplicationFiled: August 1, 2011Publication date: February 16, 2012Inventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Patent number: 8114407Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: GrantFiled: October 22, 2007Date of Patent: February 14, 2012Inventors: Walter J. Storkus, Michael S. Kinch
-
Publication number: 20120034294Abstract: Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm.Type: ApplicationFiled: December 17, 2009Publication date: February 9, 2012Applicant: ONCOTHYREON, INC.Inventors: Robert A. Dupuit, William J. Reilley
-
Patent number: 8110655Abstract: The present invention provides methods for promoting hair growth and/or treating or preventing hair loss (alopecia) by contacting the cells with a TGF-? antagonist or inhibitor either alone or in combination with other alopecia-inhibiting compounds.Type: GrantFiled: November 13, 2007Date of Patent: February 7, 2012Assignees: Auxagen, Inc., Saint Louis UniversityInventors: Jung San Huang, Shuan Shian Huang
-
Patent number: 8110554Abstract: A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases.Type: GrantFiled: October 2, 2008Date of Patent: February 7, 2012Assignee: The Regents of the University of CaliforniaInventors: Tao Jiang, Roger Y. Tsien
-
Publication number: 20120028903Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.Type: ApplicationFiled: October 6, 2009Publication date: February 2, 2012Applicant: Cambridge Enterprise LimitedInventors: John Trowsdale, Alexander Barrow, Richard Farndale
-
Publication number: 20120028888Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: November 4, 2009Publication date: February 2, 2012Inventors: Jay Janz, Athan Kuliopulos, Thomas J. McMurry